Article
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
The New England journal of medicine - 17 Sept 2020
Dummer Reinhard, Hauschild Axel, Santinami Mario, Atkinson Victoria, Mandalà Mario, Kirkwood John M, Chiarion Sileni Vanna, Larkin James, Nyakas Marta, Dutriaux Caroline, Haydon Andrew, Robert Caroline, Mortier Laurent, Schachter Jacob, Lesimple Thierry, Plummer Ruth, Dasgupta Kohinoor, Gasal Eduard, Tan Monique, Long Georgina V, Schadendorf Dirk
Abstract excerpt
BACKGROUND: In the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations. To confirm the stability of the relapse-free survival benefit, longer-term data were needed. METHODS: We randomly assigned 870 patients who...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.